David Gonzalez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7458778/publications.pdf

Version: 2024-02-01

40 papers	1,646 citations	279487 23 h-index	301761 39 g-index
40 all docs	40 docs citations	40 times ranked	3739 citing authors

#	Article	IF	Citations
1	The impact of <scp>SAMHD1</scp> expression and mutation status in mantle cell lymphoma: An analysis of the <scp>MCL</scp> Younger and Elderly trial. International Journal of Cancer, 2021, 148, 150-160.	2.3	10
2	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. Genes Chromosomes and Cancer, 2021, 60, 299-302.	1.5	16
3	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
4	The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories. HemaSphere, 2021, 5, e568.	1.2	22
5	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Advances, 2021, 5, 3188-3198.	2.5	2
6	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102.	2.3	34
7	Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical Cancer Research, 2020, 26, 608-622.	3.2	71
8	Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. Cancers, 2020, 12, 3627.	1.7	7
9	Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189.	5.8	43
10	A novel next generation sequencing approach to improve sarcoma diagnosis. Modern Pathology, 2020, 33, 1350-1359.	2.9	20
11	Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study. Blood, 2020, 136, 12-13.	0.6	0
12	Gastrointestinal Stromal Tumor With Multiple Primary Tyrosine Kinase Mutationsâ€"Clinicopathologic and Molecular Characterization. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 461-465.	0.6	4
13	NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods. Molecular Biology and Evolution, 2019, 36, 2883-2889.	3.5	1
14	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia, 2019, 33, 2241-2253.	3.3	177
15	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	1.3	44
16	Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer, 2019, 19, 582.	1.1	32
17	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia, 2019, 33, 2254-2265.	3.3	70
18	Diseaseâ€biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. Journal of Pathology, 2019, 247, 416-421.	2.1	25

#	Article	IF	Citations
19	Relevance of TP53 for CLL diagnostics. Journal of Clinical Pathology, 2019, 72, 343-346.	1.0	10
20	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. Journal of Clinical Pathology, 2018, 71, 388-394.	1.0	14
21	Detection of EGFR Variants in Plasma. Journal of Molecular Diagnostics, 2018, 20, 483-494.	1.2	37
22	An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. Human Mutation, 2018, 39, 394-405.	1.1	24
23	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. British Journal of Cancer, 2017, 116, 669-678.	2.9	48
24	Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica, 2017, 102, e57-e60.	1.7	35
25	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. Journal of Immunology, 2017, 198, 3765-3774.	0.4	61
26	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	0.8	76
27	Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. British Journal of Cancer, 2017, 117, 876-883.	2.9	98
28	Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 631-640.	1.4	28
29	Evaluation of the optimal provision of formalin-fixed, paraffin-embedded material for reverse transcription-PCR in soft-tissue tumour diagnosis. Journal of Clinical Pathology, 2017, 70, 20-24.	1.0	9
30	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16
31	Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nature Communications, 2016, 7, 13840.	5.8	32
32	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	1.3	15
33	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	6.3	132
34	Ancillary molecular analysis in the diagnosis of soft tissue tumours: reassessment of its utility at a specialist centre. Journal of Clinical Pathology, 2016, 69, 505-510.	1.0	9
35	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1029-1039.	0.5	38
36	Angiomatoid fibrous histiocytoma: comparison of fluorescence in situ hybridization and reverse transcription polymerase chain reaction as adjunct diagnostic modalities. Annals of Diagnostic Pathology, 2015, 19, 137-142.	0.6	24

#	Article	IF	Citations
37	Nextâ€generation sequencing: a change of paradigm in molecular diagnostic validation. Journal of Pathology, 2014, 234, 5-10.	2.1	68
38	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, .	3.0	46
39	Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood, 2013, 121, 3413-3419.	0.6	128
40	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood, 2003, 102, 2994-3002.	0.6	101